Phase 2 Type 1 Diabetes Trial, Recruiting (NCT06845202)

Phase 2 Type 1 Diabetes Trial, Recruiting NCT06845202 Sponsor: Alnylam Pharmaceuticals Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06845202 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part A (first phase of the trial):

People with a body mass index (BMI) between 27 and just under 40

Part B (second phase of the trial):

Adults who have been diagnosed with Type 2 diabetes
People whose HbA1c blood sugar level (a measure of average blood sugar over roughly 3 months) is between 7% and just under 10.5%
People with a BMI between 25 and just under 45
People who are on a steady, unchanged dose of either metformin alone, or metformin combined with a type of diabetes medication called an SGLT2 inhibitor

Who may not be able to join:

Part A:

People who have a known HIV infection
People who have a known current or ongoing hepatitis C or hepatitis B infection

Part B:

People who are currently taking any weight management medications or any diabetes medications other than metformin and an SGLT2 inhibitor

Note: There may be additional eligibility criteria not listed here that the trial site will assess.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Alnylam Pharmaceuticals

Phone: 1-877-ALNYLAM

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06845202

Sponsor: Alnylam Pharmaceuticals

Phase: Phase 2

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 1-877-ALNYLAM

More information: https://clinicaltrials.gov/study/NCT06845202

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Part A (first phase of the trial):

People with a body mass index (BMI) between 27 and just under 40

Part B (second phase of the trial):

Adults who have been diagnosed with Type 2 diabetes
People whose HbA1c blood sugar level (a measure of average blood sugar over roughly 3 months) is between 7% and just under 10.5%
People with a BMI between 25 and just under 45
People who are on a steady, unchanged dose of either metformin alone, or metformin combined with a type of diabetes medication called an SGLT2 inhibitor

Who may not be able to join:

Part A:

People who have a known HIV infection
People who have a known current or ongoing hepatitis C or hepatitis B infection

Part B:

People who are currently taking any weight management medications or any diabetes medications other than metformin and an SGLT2 inhibitor

Note: There may be additional eligibility criteria not listed here that the trial site will assess.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Alnylam Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

3 March 2025

Est. completion

31 August 2027

Where this trial is recruiting

🇦🇷 Argentina 🇨🇦 Canada 🇨🇱 Chile 🇩🇪 Germany 🇵🇱 Poland 🇺🇸 United States

Primary endpoints

Part A: Frequency of Adverse Events (AEs); Part B: Frequency of Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov